Cleaning validation with dirty and clean hold time demonstrates that a cleaning procedure reduces product residues and relevant contaminants to a pre-justified level and that the permissible waiting times are under control. The dirty hold time is between the end of production and the start of cleaning; the clean hold time is between completion of cleaning and the next use of the equipment.<\/p>\n
The starting point is the question of what amount of the previous substance would still be acceptable in the subsequent product. For a product changeover, a health-based exposure limit is used and a maximum permissible carryover is derived from it. This is related to the amount of the subsequent product a patient can receive daily and then translated into the detectable residue amount on product-contact surfaces.<\/p>\n
The sampling strategy must reach the most critical locations of the equipment. Swab samples are particularly suitable for seals, valves, or surfaces that are difficult to rinse; rinse samples can reflect the overall condition of a closed loop. Analytical methods require sensitivity appropriate to the limit concentration and must take recovery, selectivity, and sample handling into account.<\/p>\n
A long dirty hold time can allow residues to dry and thus change cleanability. Therefore, not only a nominal waiting time is recorded; the most unfavorable permitted period is reflected in the validation plan. For protein- or sugar-containing residues, the choice of hold time can be more decisive for the effectiveness of a cleaning cycle than an additional rinse.<\/p>\n
The clean hold time answers a different question: How long does cleaned equipment remain in a suitable condition until the next use? The definition covers storage conditions, coverings, potential recontamination, and, where necessary, microbiological aspects. If the permissible time is exceeded, the procedure determines whether the equipment must be cleaned again, rinsed, or examined before use.<\/p>\n
Calculating permissible carryover does not end with a laboratory value. It must also consider the surface area to which the result relates, the actual sampling coverage, and analytical recovery. If only part of a hard-to-access seal is sampled, an unqualified extrapolation of a swab result can underestimate the risk. This is why the validation report links the calculation approach, sampling locations, and technical rationale.<\/p>\n
The selection of the worst-case product may change when new active substances, strengths, or equipment are added. The amount of active substance alone is not a sufficient criterion, because a low-dose, highly potent substance may have a lower acceptable carryover than a high-mass, readily soluble predecessor. This makes cleaning validation a living product-family assessment.<\/p>\n
In campaign manufacturing, it must also be clear when an intermediate cleaning is sufficient and when a full validated changeover cycle is required. This decision is part of the approved cleaning instruction and not an ad hoc production decision.<\/p>\n
Repeated cleaning and subsequent re-testing until results happen to fit is not a validation approach. Validation must show that the defined cycle works under specified conditions, including unfavorable ones; a failed run is investigated as a deviation and not concealed by an undocumented repeat run.<\/p>\n
A visual inspection can detect obvious residues, but it does not, on its own, provide evidence of compliance with a toxicologically derived limit. It therefore belongs in the procedure as a supporting control. The established term validation describes the general methodology, whereas this concept brings together cleaning, sampling, carryover calculation, and both hold times.<\/p>\n
The timing of sampling after the cleaning cycle is also defined, because residual moisture or delayed drying can influence the measurement result and the subsequent microbiological assessment.<\/p>\n
In the manufacture of investigational medicinal products, small batches often share equipment that was previously used for other strengths, dosage forms, or study products. The changeover plan must therefore define which product is considered worst case, when cleaning begins after the run, and whether the cleaned line is still within its clean hold time until the next campaign. This protects against unnoticed carryover into clinical supply.<\/p>\n
Full-service CROs such as Mediconomics support the alignment of manufacturing windows and cleaning data with the clinical demand plan, the compilation of product-specific information for risk assessments, and the tracking of deviations. For QP-supported batch certification, they can consolidate the required evidence from manufacturing operations, quality control, and the supply chain.<\/p>\n
Is the dirty hold time the same for every piece of equipment?<\/strong><\/p>\n No. It depends, among other factors, on residue properties, the material of product-contact surfaces, temperature, and the approved cleaning process. Its duration is therefore justified on an equipment- and product-specific basis.<\/p>\n How is a difficult-to-clean product determined?<\/strong><\/p>\n The assessment considers toxicity, solubility, tendency to adhere, dose, and contact with critical surfaces. The result can differ significantly from the product quantity alone.<\/p>\n What happens after the clean hold time is exceeded?<\/strong><\/p>\n The approved procedure defines the required action. Depending on the risk, re-cleaning, an additional rinse, or a documented technical assessment may be necessary.<\/p>\n Cleaning validation with dirty and clean hold time demonstrates that a cleaning procedure reduces product residues and relevant contaminants to a pre-justified level and that the permissible waiting times are under control. The dirty hold time is between the end of production and the start of cleaning; the clean hold time is between completion of […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[26],"class_list":["post-8161","glossary","type-glossary","status-publish","hentry","glossary-cat-gmp-qualitaet-herstellung"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8161\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8161"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n